As shown in Figure 1A, the IC50 of lorlatinib for Huh-7 cells (22 ± 5 μmol/L) was similar to that for ALK-negative A549 NSCLC cells (19 ± 5 μmol/L), but was tens or even hundreds of thousands higher than that obtained for H2228 and H3122 NSCLC cell lines (0.9 ± 0.2 and 0.003 ± 0.0002 μmol/L, respectively) harboring ALK rearrangements (variants 3a/b and 1, respectively) [31,32]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.